Kusui Yuka1, Daisuke Nishizawa2, Junko Hasegawa2, Kyosuke Uno1,3, Hajime Miyanishi1, Hiroshi Ujike4,5, Norio Ozaki4,6, Toshiya Inada4,6, Nakao Iwata4,7, Ichiro Sora4,8, Masaomi Iyo4,9, Mitsuhiko Yamada4,10, Naoki Kondo4,11, Moo-Jun Won4,12, Nobuya Naruse4,11, Kumi Uehara-Aoyama4,13, Kazutaka Ikeda2,4, Atsumi Nitta1. 1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan. 2. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. 3. Laboratory of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata-shi, Osaka, Japan. 4. Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. 5. Ujike Nishiguchi Clinic, Okayama, Japan. 6. Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 7. Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan. 8. Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan. 9. Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan. 10. Saitama Seishin-iryo Center, Kita-adachi, Saitama, Japan. 11. Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan. 12. Koujin Hospital, Nagoya, Japan. 13. Kanagawa Psychiatric Center, Serigaya Hospital, Kanagawa, Japan.